Daphne Zohar

Daphne Zohar

Creator
0 followers

Serial biotech entrepreneur; founded PureTech Health and co-founded Karuna Therapeutics, now CEO of Seaport Therapeutics.

Awaiting Faster
SocialMay 5, 2026

Awaiting Faster

Looking forward to the implementation of quicker/less bureaucratic path to first in human and only one pivotal study required for approval. Question is when these changes will happen and will all FDA offices/divisions support.

By Daphne Zohar
Biotech M&A Poised for Second‑Busiest Year, Early Deals Surge
SocialApr 6, 2026

Biotech M&A Poised for Second‑Busiest Year, Early Deals Surge

Biotech M&A on track to have 2nd most active year in history w/ more early stage deals. Nice summary of which funds have benefited from recent M&A from Stifel @TimOpler $XBI $IBB https://t.co/udCuhIcaIi

By Daphne Zohar
Eli Lilly Acquires Centessa for $7.8B in Neuro Push
SocialMar 31, 2026

Eli Lilly Acquires Centessa for $7.8B in Neuro Push

Lilly buying $CNTA Centessa (hub & spoke R&D co) for $6.3B + $1.5B CVR. Another neuro deal. Big congrats to @Medicxi, Index ventures, General Atlantic https://t.co/jkC9dv6d3I @medicx

By Daphne Zohar
First Full GlyphAllo Data Reveal From Discovery to Human Proof‑of‑Concept
SocialMar 25, 2026

First Full GlyphAllo Data Reveal From Discovery to Human Proof‑of‑Concept

Proud of the work of our Seaport team & collaborators published today in @ScienceTM. This ~13 page peer reviewed paper is the first comprehensive data disclosure of our GlyphAllo™ program from discovery through initial human proof‑of‑concept.

By Daphne Zohar
Amy Burrough
SocialMar 25, 2026

Amy Burrough

Adding $TERN to this list (Merck $6.7B reported) led by Amy Burroughs. Congrats to Amy and team 💪 https://t.co/KZ8CtA2GA0?

By Daphne Zohar
Seeking Examples of Overly Negative Biotech Trade Press
SocialMar 16, 2026

Seeking Examples of Overly Negative Biotech Trade Press

Will ask colleagues to respond because I haven’t been tracking all the tickers. Pls reply with examples of biotech trade press being called too negative

By Daphne Zohar
China's Asset Prices Rise, Ending Bargain-Basement Era
SocialFeb 25, 2026

China's Asset Prices Rise, Ending Bargain-Basement Era

Assets from China are ubiquitous but China is no longer the 'bargain basement' in terms of deals. Will be interesting to see how rising prices impact deal interest https://t.co/yM3P28QCDc $XBI $IBB $BBC https://t.co/W61XACPX7O

By Daphne Zohar
Daré Bioscience Launches Reg A Crowdfunding for Women's Health
SocialFeb 12, 2026

Daré Bioscience Launches Reg A Crowdfunding for Women's Health

Daré Bioscience with an approved product and a pipeline in women’s health is raising money from investors in a crowdfunding like construct (reg A offering with minimum investment of $250). https://t.co/NA3JKe6Irg haven’t seen too many of these

By Daphne Zohar